BeiGene

BeiGene

Yahoo Finance • 7 days ago

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. S... Full story

Yahoo Finance • 12 days ago

State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?

Key Points State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to the 0.55% charged by First Trust NYSE Arca Biotechnology Index Fund. First Trust's fund focuses exclusively on 30 b... Full story

Yahoo Finance • 18 days ago

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

The First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides concentrated, high-conviction exposure to biotechnology firms, while the Vanguard Health Care ETF (NYSEMKT:VHT) offers a cheaper, diversified basket across the entir... Full story

Yahoo Finance • 19 days ago

A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position

Key Points CEO John Oyler sold nearly 110,000 American Depositary Shares for $34.6 million at a weighted average price of $315.28 per share. The shares were sold under a pre-established Rule 10b5-1 trading plan. John Oyler retains Ordinar... Full story

Yahoo Finance • 20 days ago

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

Key Points iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio... Full story

Yahoo Finance • 28 days ago

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

Quick Read SK hynix surged 13% on its Nasdaq debut, raising $26.5 billion in what stands as the largest U.S. equity sale by a foreign company ever. Circle Internet Group (CRCL) surged 15% on OCC bank approval as Capital One (COF) earned a... Full story

Yahoo Finance • last month

Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list. TheFly reported on June 2 that RBC Capital analyst Leon... Full story

Yahoo Finance • 2 months ago

Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth

(RTTNews) - Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth, who has served as Chairman of Kymera sinc... Full story

Yahoo Finance • 2 months ago

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made... Full story

Yahoo Finance • 2 months ago

BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA

BeOne Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, BeOne Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approv... Full story

Yahoo Finance • 3 months ago

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline SAN CARLOS, Calif., May 21, 2026--(BUSINESS WIRE)--BeOn... Full story

Yahoo Finance • 3 months ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 3 months ago

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics(NASDAQ:NKTR). The estimated value of the trade was... Full story

Yahoo Finance • 3 months ago

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potenti... Full story

Yahoo Finance • 3 months ago

Did FDA Fast-Track HER2 Regimen Just Shift BeOne Medicines' (ONC) Investment Narrative?

On 29 April 2026, BeOne Medicines announced that the FDA granted Priority Review to an sBLA for TEVIMBRA with ZIIHERA and chemotherapy, alongside Breakthrough Therapy Designation for ZIIHERA-based regimens in first-line treatment of unrese... Full story

Yahoo Finance • 4 months ago

Here are the major earnings after the close Wednesday

Major earnings expected after the bell on Wednesday include: * SL Green Realty Corp. (SLG [https://seekingalpha.com/symbol/SLG]) * J.B. Hunt Transport Services (JBHT [https://seekingalpha.com/symbol/JBHT]) * BeOne Medicines AG (ONC... Full story

Yahoo Finance • 4 months ago

BeiGene Q1 2026 Earnings Preview

* BeiGene (ONC [https://seekingalpha.com/symbol/ONC]) is scheduled to announce Q1 earnings results on Wednesday, April 15th, after market close. * The consensus EPS Estimate is $0.85 [https://seekingalpha.com/symbol/ONC/earnings/estima... Full story

Yahoo Finance • 4 months ago

BeOne wins China approval for Amgen’s lung cancer drug Imdelltra

[Approved stamp on application form or business agreement document] * BeOne Medicines (ONC [https://seekingalpha.com/symbol/ONC]) announced on Friday that Chinese officials granted conditional approval for tarlatamab, a bispecific T-cel... Full story

Yahoo Finance • 4 months ago

BeOne Medicines price target lowered to $411 from $412 at Truist

Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across... Full story

Yahoo Finance • 4 months ago

Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform Rating

BeOne Medicines AG (NASDAQ:ONC) is one of the 7 Fastest Growing European Stocks to Invest In. On March 26, 2026, Wolfe Research analyst Kalpit Patel initiated coverage on BeOne Medicines AG (NASDAQ:ONC) with an Outperform rating and a $34... Full story